Press & News

ViewReleaseInStandardHtml

Boule Diagnostics – First day for trading after the division of shares (stock split 4:1)

At the Annual General Meeting (”AGM”) of Boule Diagnostics AB (”Boule”) on May 14, 2018 it was decided that a division of Boule’s shares will be implemented, whereby each current share will be divided into four shares (so called stock split 4:1). Today Friday, June 1, 2018, is the first day for trading after the division of Boule’s shares.

The new ISIN code is: SE0011231158 (previously: SE0000437402).

The record date for the division of shares is Monday, June 4, 2018. Shares received through the division are projected to be registered on the respective holders’ accounts by Tuesday, June 5, 2018.

The division of the company’s shares will occur through an automatic process handled by Euroclear Sweden AB and shareholders do not need to take any action. After the division of shares, Boule's total number of shares will increase from 4,854,138 shares to 19,416,552 shares.

For further information, please contact:

Peter Ehrenheim, Chairman of the Board Boule Diagnostics AB, phone 0706-67 57 11
Fredrik Dalborg, CEO and Group President Boule Diagnostics AB, phone 070-558 51 05

About Boule Diagnostics AB (publ)

Boule Diagnostics AB is a global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden, the USA and Mexico. The company products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011. www.boule.com 

The information was submitted for publication, through the agency of the contact person set out above, at 08.45 CET on June 1, 2018.